Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»BioTech»Envision Pharma Group Announces Appointment of Dr. Deepti Sodhi Jaggi to Board of Directors
    BioTech

    Envision Pharma Group Announces Appointment of Dr. Deepti Sodhi Jaggi to Board of Directors

    Marie JonesBy Marie JonesMay 10, 2023No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Envision Pharma Group (Envision) today announced the appointment of Dr. Deepti Sodhi Jaggi to the Envision Board of Directors.

    “We are pleased to welcome Deepti to the Envision Board of Directors,” shares Meg Heim, CEO of Envision Pharma Group. “Deepti’s deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner.”

    Dr. Jaggi’s career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.

    Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.

    Dr. Jaggi’s previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.

    “I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives,” says Dr. Jaggi.

    Dr. Jaggi’s educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business.

    About Envision Pharma Group
    Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

    Contact Information
    Colleen Carter
    Associate Director, Communications, Office of the CEO
    colleen.carter@envisionpharma.com
    1 (508) 505 8856

    SOURCE: Envision Pharma Group

    Envision Pharma Group
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleNissin Foods Announces 2023 Q1 Financial Results
    Next Article Metallic Minerals Announces $6.3 Million Strategic Equity Investment by Newcrest Mining

    Related Posts

    Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, further enhancing patient access to the medication

    June 24, 2026

    JBM Healthcare Announces FY2026 Annual Results

    June 22, 2026

    CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

    June 22, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.